Yan Ji
Hematology & Oncology · Saint Paul, MNNPI 1225355829
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $126,559 of the $164,338 with a category attached, or 77.0%. 18 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. 2025 is the largest year on record at $88,182, more than ten times the $19 reported in 2020. Among hematology & oncology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $1095.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$46K
- Daiichi Sankyo Inc.$39K
- Johnson & Johnson$19K
- E.r. Squibb & Sons, L.L.C.$14K
- Merck$10K
- Janssen Scientific Affairs, LLC$9K
- plus $28K from 12 others
Across 500 payments — averaging $12,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.5M
- Novartis$1.7M
- Servier Bioinnovation$473K
- Genentech, Inc.$427K
- Merck$194K
- Seagen Inc.$133K
- plus $811K from 12 others
What the payments were for
- Consulting fees$126,55977%
- Speaking & faculty fees$27,64017%
- Travel & lodging$8,3375%
- Food & beverage$1,7641%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 31 | $46,381 |
| Daiichi Sankyo Inc. | 33 | $39,474 |
| Johnson & Johnson | 26 | $19,148 |
| E.r. Squibb & Sons, L.L.C. | 18 | $13,516 |
| Merck | 11 | $9,509 |
| Janssen Scientific Affairs, LLC | 7 | $8,543 |
| Amgen | 4 | $8,100 |
| Beigene USA, Inc. | 2 | $4,550 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $3,323 |
| Astellas Pharma Global Development | 1 | $2,172 |
| Beone Medicines USA, Inc. | 1 | $1,950 |
| Deciphera Pharmaceuticals Inc. | 5 | $1,841 |
| Novartis | 2 | $1,656 |
| Genentech, Inc. | 2 | $1,578 |
| Seagen Inc. | 1 | $1,250 |
| Genentech USA, Inc. | 1 | $998 |
| Novocure GmbH | 1 | $200 |
| Tempus AI, Inc | 1 | $151 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,338 in reported general payments places this provider in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 43 | $536,767 |
| RevlimidLenalidomide | 22 | $493,799 |
| Lenalidomide | 20 | $216,043 |
| BesremiRopeginterferon Alfa-2b-Njft | 12 | $209,110 |
| BraftoviEncorafenib | 11 | $159,254 |
| MektoviBinimetinib | 11 | $151,514 |
| EliquisApixaban | 36 | $31,725 |
| XareltoRivaroxaban | 16 | $18,736 |
| Abiraterone Acetate | 26 | $3,886 |
| Anastrozole | 107 | $3,263 |
| Exemestane | 11 | $1,543 |
| Acyclovir | 34 | $1,084 |
| Tamoxifen Citrate | 34 | $985 |
| Dexamethasone | 96 | $823 |
| Hydroxyurea | 21 | $676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $4,550 | $536,76743 claims |
| Johnson & JohnsonXarelto | $19,148 | $18,73616 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $8,543 | $3,88626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Saint Paul
- Kurt DemelSaint Paul$22K
- Daniel AndersonSaint Paul$5K
- Charlene FaresSaint Paul$4K
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Sagar PatelEdina$389K
- Vicki MorrisonMinneapolis$354K
- Deepti BehlRochester$205K
- Aimee MerinoMinneapolis$161K
- Yucai WangRochester$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.